Dipivoxil

I joined Gilead Sciences in 1990, and by 1999 we were in the final stage of about five or six years of work in creating the drug adefovir dipivoxil to treat H.I.V. The drug wasn’t approved by the F.D.A. for H.I.V. because the data showed evidence of kidney toxicity.